Review of eight trials finds evidence too sparse on GLP-1 bone effects

The wire

1. 01The PRISMA-compliant review pooled no data across eight randomized trials (n=493) of DXA-measured bone mineral density, covering exenatide in five trials, liraglutide in two, and semaglutide and dulaglutide in one each.
2. 02Clinicians fielding questions about bone loss during rapid weight reduction now have a formal statement that the randomized evidence is insufficient per agent.
3. 03Five of eight trials raised risk-of-bias concerns on randomization and selective reporting, and most enrolled adults with type 2 diabetes rather than obesity alone.

From the source

Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review

Archives of osteoporosis · 2026 Oct 23 · Lai CH, Li YT, Wu TS et al.